J. Witjes, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Janssen; Ferring; AstraZeneca
    Date added:
    Date updated:
    12/22/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Sanofi; MSD; BMS; Ipsen; Nucleix Ltd; Astellas
    Date added:
    Date updated:
    12/22/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    BMS, Tocagen, MSD, Roche
    Date added:
    Date updated:
    12/22/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Spectrum, Taris, BioCanCell, Cepheid, Nucleix
    Date added:
    Date updated:
    12/22/2021
Return to Management of Non Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems Webcast (2021)